Stock Scorecard

Stock Summary for ARS Pharmaceuticals Inc (SPRY) - $14.88 as of 4/17/2025 9:57:39 PM EST

Total Score

13 out of 30

Safety Score

45 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for SPRY

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for SPRY

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for SPRY

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for SPRY

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for SPRY (45 out of 100)

Stock Price Rating (Max of 10) 5
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 8
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 1
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for SPRY

Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday - China Liberal Education ( NASDAQ:CLEU ) , Capricor Therapeutics ( NASDAQ:CAPR ) 3/20/2025 2:43:00 PM
ARS Pharmaceuticals, Inc. ( SPRY ) Q4 Earnings and Revenues Beat Estimates 3/20/2025 12:25:00 PM
FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment - ARS Pharmaceuticals ( NASDAQ:SPRY ) 3/6/2025 2:51:00 PM
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg ( epinephrine nasal spray ) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms - ARS Pharmaceuticals ( NASDAQ:SPRY ) 3/5/2025 9:10:00 PM
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg ( epinephrine nasal spray ) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms 3/5/2025 9:10:00 PM
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences - ARS Pharmaceuticals ( NASDAQ:SPRY ) 3/3/2025 9:35:00 PM
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences 3/3/2025 9:35:00 PM
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® ( Epinephrine Nasal Spray ) to National Formularies, Further Expanding Coverage for Patients 2/21/2025 12:02:00 AM
Allergy Treatment Market Size is Projected to Reach USD 64.65 billion by 2033, Growing at a CAGR of 6.46%: Straits Research 1/22/2025 2:55:00 PM
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools - ARS Pharmaceuticals ( NASDAQ:SPRY ) 1/21/2025 1:00:00 PM

Financial Details for SPRY

Company Overview
Ticker SPRY
Company Name ARS Pharmaceuticals Inc
Country USA
Description ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to food, medication, and insect stings. The company is headquartered in San Diego, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 5/7/2025

Stock Price History
Last Day Price 14.88
Price 4 Years Ago 6.66
Last Day Price Updated 4/17/2025 9:57:39 PM EST
Last Day Volume 1,550,090
Average Daily Volume 2,078,306
52-Week High 18.51
52-Week Low 7.55
Last Price to 52 Week Low 97.09%

Valuation Measures
Trailing PE 186.00
Industry PE 37.77
Sector PE 39.26
5-Year Average PE 25.82
Free Cash Flow Ratio 28.62
Industry Free Cash Flow Ratio 17.82
Sector Free Cash Flow Ratio 38.99
Current Ratio Most Recent Quarter 14.26
Total Cash Per Share 0.52
Book Value Per Share Most Recent Quarter 2.62
Price to Book Ratio 5.69
Industry Price to Book Ratio 9.37
Sector Price to Book Ratio 22.22
Price to Sales Ratio Twelve Trailing Months 16.38
Industry Price to Sales Ratio Twelve Trailing Months 88.13
Sector Price to Sales Ratio Twelve Trailing Months 24.77
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 0

Share Statistics
Total Shares Outstanding 98,120,000
Market Capitalization 1,460,025,600
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 114.71%
Reported EPS 12 Trailing Months 0.08
Reported EPS Past Year 0.00
Reported EPS Prior Year 0.07
Net Income Twelve Trailing Months 7,998,000
Net Income Past Year 7,998,000
Net Income Prior Year -54,365,000
Quarterly Revenue Growth YOY 4,900.00%
5-Year Revenue Growth -46.80%
Operating Margin Twelve Trailing Months 54.50%

Balance Sheet
Total Cash Most Recent Quarter 50,817,000
Total Cash Past Year 50,817,000
Total Cash Prior Year 70,971,000
Net Cash Position Most Recent Quarter 50,817,000
Net Cash Position Past Year 50,817,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 8,409,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 256,798,000
Total Stockholder Equity Prior Year 230,760,000
Total Stockholder Equity Most Recent Quarter 256,798,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months 12,985,000
Free Cash Flow Per Share Twelve Trailing Months 0.13
Free Cash Flow Past Year 12,985,000
Free Cash Flow Prior Year -59,441,000

Options
Put/Call Ratio 0.57
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.27
MACD Signal 0.25
20-Day Bollinger Lower Band 9.93
20-Day Bollinger Middle Band 12.19
20-Day Bollinger Upper Band 14.45
Beta 0.98
RSI 56.02
50-Day SMA 11.92
150-Day SMA 8.17
200-Day SMA 9.20

System
Modified 4/17/2025 12:32:42 PM EST